Status:
COMPLETED
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
Lead Sponsor:
Pharmassist Ltd
Collaborating Sponsors:
University of Athens
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantl...
Detailed Description
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantl...
Eligibility Criteria
Inclusion
- Female aged ≥ 18 years of age.
- Histological confirmed ER+/HER2- metastatic Breast Cancer prior to beginning a treatment
- Life expectancy permits participation to the study.
- Available tumor tissue sample for molecular analysis.
- Signed informed consent form.
Exclusion
- Female younger than 18 years old.
- History of another malignancy within 3 years or current 2nd primary malignancy.
- Patients that have not signed the informed consent.
Key Trial Info
Start Date :
October 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 8 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04480814
Start Date
October 11 2019
End Date
February 8 2022
Last Update
December 30 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University General Hospital of Alexandroupoli
Alexandroupoli, Alexandroupolis, Greece, 68100
2
Aretaieio University Hospital of Athens
Athens, Attica, Greece, 11528
3
University General Hospital of Athens Attikon
Athens, Attica, Greece, 124 62
4
Metropolital Hospital
Piraeus, Piraeus, Greece, 18547